Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Convertible Debt (2023 - 2024)

Historic Convertible Debt for Ernexa Therapeutics (ERNA) over the last 2 years, with Q3 2024 value amounting to $32.0 million.

  • Ernexa Therapeutics' Convertible Debt rose 82807.07% to $32.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $32.0 million, marking a year-over-year increase of 82807.07%. This contributed to the annual value of $6.8 million for FY2023, which is N/A changed from last year.
  • Per Ernexa Therapeutics' latest filing, its Convertible Debt stood at $32.0 million for Q3 2024, which was up 82807.07% from $8.9 million recorded in Q2 2024.
  • Over the past 5 years, Ernexa Therapeutics' Convertible Debt peaked at $32.0 million during Q3 2024, and registered a low of $3.5 million during Q3 2023.